These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 991150

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase I trial of dianhydrogalactitol administered Iv in a weekly schedule.
    Vogel CL, Winton EF, Moore MR, Sohner S.
    Cancer Treat Rep; 1976 Jul; 60(7):895-901. PubMed ID: 795538
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.
    Ahmann DL, Bisel HF, Edmonson JH, Hahn RG, O'Connell MJ, Frytak S.
    Cancer Treat Rep; 1976 Nov; 60(11):1681-2. PubMed ID: 1021239
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase I study of a five-day intermittent schedule for 1,2:5,6-dianhydrogalactitol (NSC-132313).
    Eagan RT, Moertel CG, Hahn RG, Schutt AJ.
    J Natl Cancer Inst; 1976 Jan; 56(1):179-81. PubMed ID: 943554
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of dianhydrogalactitol in metastatic malignant melanoma: a Southwest Oncology Group study.
    Thigpen JT, Al-Sarraf M, Hewlett JS.
    Cancer Treat Rep; 1979 Apr; 63(4):525-8. PubMed ID: 445506
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas.
    Edmonson JH, Frytak S, Letendre L, Kvols LK, Eagan RT.
    Cancer Treat Rep; 1979 Apr; 63(11-12):2081-3. PubMed ID: 526941
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
    Judson IR, Calvert AH, Rutty CJ, Abel G, Gumbrell LA, Graham MA, Evans BD, Wilman DE, Ashley SE, Cairnduff F.
    Cancer Res; 1989 Oct 01; 49(19):5475-9. PubMed ID: 2670205
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
    Nicaise C, Rozencweig M, Crespeigne N, Dodion P, Gerard B, Lambert M, Decoster G, Kenis Y.
    Cancer Treat Rep; 1986 May 01; 70(5):599-603. PubMed ID: 3708609
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Preclinical toxicologic evaluation of dianhydrogalactitol in dogs and monkeys.
    Folk RM, Pavkov KL, Thake DC.
    Cancer Treat Rep; 1976 Oct 01; 60(10):1585-9. PubMed ID: 828520
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.